179 related articles for article (PubMed ID: 38429605)
1. Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistance.
Mohammadipoor N; Naiebi R; Mazhari SA; Amooei F; Owrang M; Dastghaib S; Shams M; Maleki MH; Dastghaib S
Mol Biol Rep; 2024 Mar; 51(1):379. PubMed ID: 38429605
[TBL] [Abstract][Full Text] [Related]
2. Targeting apoptosis and unfolded protein response: the impact of β-hydroxybutyrate in clear cell renal cell carcinoma under glucose-deprived conditions.
Roohy F; Siri M; Kohansal K; Ghalandari A; Rezaei R; Maleki MH; Shams M; Monsef A; Dastghaib S
Mol Biol Rep; 2024 Jan; 51(1):168. PubMed ID: 38252187
[TBL] [Abstract][Full Text] [Related]
3. Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2α and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line.
Pajdzik K; Wilamowski M; Żurawek D; Stopa KB; Nodzyński M; Kalita A; Jura J
IUBMB Life; 2020 Aug; 72(8):1807-1818. PubMed ID: 32593213
[TBL] [Abstract][Full Text] [Related]
4. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
5. [Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof].
Zhang N; Gong K; Yang XY; Xin DQ; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(22):1526-9. PubMed ID: 16854277
[TBL] [Abstract][Full Text] [Related]
6. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL
Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533
[TBL] [Abstract][Full Text] [Related]
7. [Activation of HIF-1α/ACLY signaling axis promotes progression of clear cell renal cell carcinoma with VHL inactivation mutation].
Ma Y; Wang YH; Huang S; Zou ZG; Hu L; Guo LC
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1230-1236. PubMed ID: 38058039
[No Abstract] [Full Text] [Related]
8. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
9. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
[TBL] [Abstract][Full Text] [Related]
10. Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
Pasha M; Sivaraman SK; Frantz R; Agouni A; Munusamy S
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30909494
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
13. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
16. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
17. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
18. Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines.
Swiatek M; Jancewicz I; Kluebsoongnoen J; Zub R; Maassen A; Kubala S; Udomkit A; Siedlecki JA; Sarnowski TJ; Sarnowska E
IUBMB Life; 2020 Jun; 72(6):1220-1232. PubMed ID: 32250548
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
[TBL] [Abstract][Full Text] [Related]
20. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]